Latest news with #BauschHealthCompaniesInc
Yahoo
07-08-2025
- Business
- Yahoo
Bausch Health Announces 2025 Gastrointestinal Health Scholars Program Winners
For the Sixth Consecutive Year, 10 Students with Gastrointestinal Disease Will Each Receive a $10,000 Scholarship LAVAL, QC / / August 7, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), today announced the recipients of its 2025 Salix Gastrointestinal Health Scholars Program. For the sixth year, Bausch Health is proud to award 10 deserving students living with a GI disease $10,000 each to further their higher education. "The overwhelming response to our scholarship program reflects the unwavering drive and determination of students within the GI community. These remarkable individuals refuse to let their illness define their path," said Aimee Lenar, Executive Vice President, US Pharma, Bausch Health. "Each year, we are inspired by their stories of resilience, which serve as powerful reminders of true strength. Bausch Health is proud to continue providing meaningful financial support to help ease their burden and empower their academic success." The 2025 scholarship recipients were chosen from a competitive pool of over 370 applicants. As part of the selection process, candidates submitted personal essays detailing how their gastrointestinal condition has shaped their educational journey and highlighting the support provided by their health care providers in helping them achieve their academic and personal milestones. All applications were thoroughly evaluated by an independent panel of judges. The program recognizes students across a wide range of educational pursuits, with scholarships in three categories, including the Undergraduate Scholar Awards, for those pursuing undergraduate degrees; the Graduate Scholar Awards, for those pursuing graduate degrees; and the Working and/or Single Parent's Scholar Award, for students who are working and/or single parents pursuing undergraduate, vocational/technical, or graduate degrees. This year's recipients shared powerful reflections on what Bausch Health's Salix Gastrointestinal Health Scholars Award means to them and how it's helping shape their academic journey. "Although my diagnosis has provided many challenges, it has ultimately fueled my desire to become a physician. I have found a passion for helping others, and I plan to become a pediatric gastroenterologist," said Alexis Weary, a scholarship recipient. "I truly appreciate the company for their work in gastrointestinal healthcare and for providing me with this scholarship to help me turn my dreams into a reality." Another scholarship recipient, Samantha Smith said, "This scholarship affirms my belief that chronic illness can be a source of resilience and innovation. I'm deeply grateful to Bausch Health's Salix Gastrointestinal Health Scholars Program for empowering me to continue advocating for inclusive policy reformation." Their words reflect the heart of the program-empowering students to pursue their goals with confidence, support, and pride. Bausch Health's 2025 Salix Gastrointestinal Health Scholars Program recipients are: Undergraduate Scholar Awards Krish Desai - University of California Los Angeles (UCLA) Maya Fischler - Brown University Annie Jones - Colorado State University Ethan Leicht - Louisville State University Maggie Schaefer - Creighton University Keaton Van Nostrand - Florida State University Graduate Scholar Awards Kunika Chahal - SUNY Downstate College of Medicine Samantha Smith - Harvard Business School Alexis Weary - Nova Southeastern University College of Osteopathic Medicine Working and/or Single Parent's Scholar Award Miriam McCarter - Brigham Young University Law School To learn more about Bausch Health's Salix Gastrointestinal Health Scholars Program, visit or visit About Bausch Health Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is a global, diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neurology, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb Corporation. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors. Our gastroenterology business, Salix Pharmaceuticals, is one of the largest specialty pharmaceutical businesses in the world and has licensed, developed and marketed innovative products for the treatment of gastrointestinal diseases for more than 30 years. For more information about Salix, visit and connect with us on Twitter and LinkedIn. For more information about Bausch Health, visit and connect with us on LinkedIn. Investor Contact: Media Contact: Garen Sarafian Katie Savastano ir@ 877-281-6642 (toll-free) 908-569-3692 SOURCE: Bausch Health Companies Inc. View the original press release on ACCESS Newswire
Yahoo
11-07-2025
- Business
- Yahoo
Bausch Health Companies (BHC) Canada Announces Expanded Availability of CABTREO Gel
Bausch Health Companies Inc. (NYSE:BHC) is one of the 13 Best Healthcare Stocks to Buy Under $10. On July 9, Bausch Health Companies Inc. (NYSE:BHC), Canada, announced the availability of CABTREO gel 1.2% w/w, 0.15% w/w, and 3.1% w/w to beneficiaries of the public drug plans of Nova Scotia and Ontario. A series of pharmaceutical and medical products in a warehouse, displaying the range of products available. The gel, which treats acne vulgaris, would also be available through the federal government's Non-Insured Health Benefits drug plan for Indigenous populations and that of the Correctional Service of Canada. CABTREO treats acne vulgaris in patients aged 12 and older, and is the first and only triple-combination topical treatment for acne that is approved by Health Canada. It has three action mechanisms as an antibiotic, a retinoid, and an antibacterial agent. Bausch Health Companies Inc. (NYSE:BHC) develops, manufactures, and markets a range of generic, branded, and branded generic pharmaceuticals, over-the-counter products, and medical devices. The company operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. While we acknowledge the potential of BHC as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
14-06-2025
- Business
- Yahoo
Bausch Health (BHC) Jumps 8.5% as Exec Hikes Stake; Subsidiaries Raise Over $3-Billion Fresh Funds
We recently published a list of . In this article, we are going to take a look at where Bausch Health Companies Inc. (NYSE:BHC) stands against other best-performing stocks of Friday. Bausch Health extended its winning streak to a sixth consecutive day on Friday, ending 8.53 percent higher at $5.98 apiece after one of its directors acquired $15 million worth of shares in the company. In a regulatory filing on Thursday, Bausch Health Companies Inc. (NYSE:BHC) said that its director, John Paulson, acquired nearly 2.79 million new shares through his company, Paulson Capital Inc., at a price of $5.05 to $5.47 apiece. A series of pharmaceutical and medical products in a warehouse, displaying the range of products available. No reason was divulged regarding the transaction, but investors may have taken the acquisition as a cue to bargain-hunt on its shares. Paulson's acquisition followed the listed firm's regulatory filing earlier this week that one of its direct subsidiaries and two indirect subsidiaries are planning to raise more than $3 billion in fresh funds through the issuance of a loan facility and revolving credit facility. On Tuesday, the listed firm's direct arm, Bausch + Lomb Corporation, launched a 600-million euro ($693 million) senior notes offering on Tuesday. This was on top of another $3 billion being raised by two indirect subsidiaries through a term B loan facility amounting to $2.2 billion and a revolving credit facility worth $800 million. Bausch Health Companies Inc. (NYSE:BHC) said funds from the fundraising program will be used for the repayment of its direct subsidiary's existing revolving credit facility, refinancing of term loans due 2027, and paying other fees and expenses, as well as general corporate purposes. While we acknowledge the potential of BHC as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
07-05-2025
- Business
- Yahoo
Bausch Health Companies Inc. (BHC): Among Billionaire John Paulson's Stocks with Huge Upside Potential
We recently published a list of Billionaire John Paulson's 10 Stocks with Huge Upside Potential. In this article, we are going to take a look at where Bausch Health Companies Inc. (NYSE:BHC) stands against other stocks with huge upside potential. John Alfred Paulson is an American billionaire hedge fund manager who founded Paulson & Co. in 1994. It is a New York-based fund management firm that specializes in private equity and hedge funds. Paulson graduated as valedictorian of his class with a summa cum laude distinction in finance from NYU's College of Business and Public Administration in 1978. He also pursued an MBA at Harvard Business School as a George F. Baker Scholar, which is a prestigious recognition awarded to the top 5% of his class. It's supported by the Sidney J. Weinberg/Goldman Sachs scholarship, which he earned in 1980. With a client base of 20, the firm's latest 13F filing for Q4 2024 revealed ~$1.65 billion in managed 13F securities and a top 10 holdings concentration of 98.55%. The firm is known for its expertise in event-driven arbitrage strategies, such as merger arbitrage, bankruptcy reorganizations, and other corporate events. Paulson & Co. also pursues investments in distressed debt opportunities throughout the US and Western Europe, with the help of its strategic insights and extensive market experience. John Paulson is now also bullish on gold after 15 years and expects its price to reach ~$5,000 per ounce by 2028. He is the largest shareholder in Perpetua Resources. On April 29, Reuters reported that in a recent interview, Paulson reinforced that his conviction in gold is underpinned by the analysis of central bank buying trends and rising global trade tensions. He highlighted the inclination of central banks and individuals to seek stable stores of value now and suggested that gold will therefore enhance its global standing. Paulson believes that the Western confiscation of Russia's foreign reserve holdings following the Ukraine invasion is one of the reasons behind the anticipated appreciation of gold prices. Our Methodology To compile the list of billionaire John Paulson's 10 stocks with huge upside potential, we sifted through Q4 2024 13F filings of Paulson & Co. from Insider Monkey. From these filings, we checked each stock's upside potential from CNN and ranked the stocks in ascending order of this upside potential. We have also added Paulson & Co.'s stake in each company and the hedge fund sentiment around each stock. Note: All data was sourced on May 2. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
Yahoo
23-04-2025
- Business
- Yahoo
Is Bausch Health Companies Inc. (BHC) the Best Canadian Penny Stock to Invest in Now?
We recently published a list of In this article, we are going to take a look at where Bausch Health Companies Inc. (NYSE:BHC) stands against other best Canadian penny stocks to invest in now. We define penny stocks as shares trading under $5.00, which usually fall into the small cap category. As illustrated by the performance of thematic ETFs, the small cap factor, which performed well historically, fell out of favor sometime in the mid-2010s and has kept underperforming ever since. The 2023-2024 period brought even stronger underperformance of penny stocks, as the proliferation of the AI trend created disproportionate opportunities across the market, favoring only a handful of large capitalization big tech names. This was an important factor in explaining the difference in cross-country stock market returns as well – for example, the Canadian stock market has largely moved in sync or even occasionally outperformed the US market during the first decade of the century, until a noticeable decoupling took place in the early 2010s. Besides lagging on productivity improvement and different monetary policies, the size factor clearly played a role, as Canada lacks big tech players to capitalize on the rapid technological advancements that took place during the 2010s. READ ALSO: 10 Best Canadian Stocks to Buy According to Billionaires As a result, both the Canadian and small-size factors have found themselves at multi-year lows relative to the US stock market at the end of calendar 2024. While many investors make reactive decisions and avoid stocks with historical underperformance, the smart way to make money is to often take contrarian bets based on forward-looking signals that may suggest a reversal in the previous tendencies. The main questions to answer in this article are the following: will the small cap factor and Canada stocks become favored again and able to outperform their large cap and US counterparts? When discussing the small factor, we get to see that its recent 2023-2024 underperformance was accelerated by rising stock market concentration to record levels. External data suggests that the 2024 US stock market concentration, as measured by the share of the top 10 largest companies in the total market, was at a record 38%, significantly above the historical average of around 24%. This means that most of the stock market returns were driven by a handful of companies favored by AI-related FOMO which overstretched their market valuations. In a scenario where large caps perform well, the small caps fall out of favor automatically, by setup. History shows, however, that concentration tends to revert to the mean – this is already happening in 2025 as the Magnificent 7 ETF, which includes the largest big tech stocks, has significantly underperformed the broad market, decreasing its concentration. Furthermore, the small cap factor tends to perform well when the economy is growing, interest rates are low and capital moves freely to riskier assets – while we aren't there yet, the stock market is a forward-looking animal that tends to anticipate economic developments 6-12 months ahead. We believe small caps and particularly penny stocks may start performing well in anticipation of lower interest rates and better economic conditions in 2026 and beyond, past the current tariff turmoil and other uncertainties induced by rapid policy changes brought by the new US administration. There are reasons to expect an improvement in the performance of Canadian stocks relative to the US market. First, the Trump Tariff Turmoil has much worse potential implications for the US than it does for Canada – the US has put its entire export/import base at risk of retaliation, while Canada only risks tariffs for its US exports (and likely at a lower overall tariff rate). Second, the breaking of economic and ideological ties with the new US administration could lead to an overall mobilization of the Canadian people and political class, and drive several positive developments: (1) substitution of US consumer brands with local Canadian brands; (2) accelerating investments into the mining/energy infrastructure and pipelines to create alternative paths and markets for the main Canadian product, which is commodities. Both (1) and (2) would have positive implications for the entire Canadian stock market and economy. The main takeaway for readers is that combining the small size factor with the Canadian factor could lead to substantial outperformance relative to the US market which witnesses heightened uncertainty and negative returns year-to-date. In such a scenario, Canadian penny stocks appear the ideal securities to pick for a bet on both factors, which would be contrarian to the trends we witnessed in the last 10 years. To compile our list of best Canadian penny stocks we use a stock screener to filter for Canadian companies trading in the US with a stock price below $5.00. Then we compared the list with our proprietary Q4 2024 database of hedge funds' ownership and included in the article the top 13 stocks with the largest number of hedge funds owning the stock, ranked in ascending order. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (). A series of pharmaceutical and medical products in a warehouse, displaying the range of products available. Bausch Health Companies Inc. (NYSE:BHC) is a pharmaceutical and medical device company. Through its Bausch + Lomb segment, the company focuses on eye health products (a range of vision care, surgical, and ophthalmic pharmaceutical products). The International Rx segment handles branded and generic pharmaceutical products outside the US, and the Diversified Products segment includes neurology and other therapeutic areas. BHC is a global player with operations in more than 100 countries, and ranked first on our recent list of 12 Best Low Price Pharma Stocks To Invest In Right Now. Bausch Health Companies Inc. (NYSE:BHC) delivered strong results in the latest reported Q4, marking its seventh consecutive quarter of revenue and adjusted EBITDA growth. The company's Q4 2024 revenues increased 4% on a reported basis and 7% on an organic basis, driven by strong organic growth in the Salix and Solta segments. For the full year 2024, revenues increased 5% on a reported basis and 6% on an organic basis, with all four segments delivering revenue and segment profit growth. The company generated approximately $1.3 billion in adjusted operating cash flow for the full year, exceeding guidance. Looking ahead, Bausch Health Companies Inc. (NYSE:BHC) is focused on three fundamental value-creation pillars: enhancing operational assets, unlocking the full value of its Bausch + Lomb equity stake, and optimizing capital structure. The company has made substantial progress in strengthening its leadership team with key appointments in critical areas, including a new CFO. The company's innovation efforts have shown progress, particularly with the approval of Thermage FLX in China and the development of AI-enabled tools for Xifaxan sales, which secures its 3rd place on our list of the best Canadian penny stocks. Overall, BHC ranks 3rd on our list of best Canadian penny stocks to invest in now. While we acknowledge the potential of BHC to grow, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than BHC but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
